Lantus is a long-acting modified version of human insulin (insulin analog) used to control blood sugar in patients with Type 1 and Type 2 diabetes.
To report any serious adverse events associated with the use of this drug, please contact the FDA MedWatch program using the contact information at the bottom of this page.
FDA Drug Safety Communication: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer
- FDA Drug Safety Podcast: Update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer [ARCHIVED]
Early Communication About Safety of Lantus (insulin glargine)[ARCHIVED]